Radiomics Predicts Survival in Colorectal Liver Metastases Treated with TACE

Colorectal cancer frequently metastasizes to the liver, with only approximately 20% of patients presenting with resectable disease at the time of diagnosis [1]. For the majority with unresectable colorectal liver metastases, regional therapies such as drug-eluting bead transarterial chemoembolization (TACE, a procedure where microspheres deliver concentrated chemotherapy directly to the tumor arterial supply) using irinotecan have emerged as important options, particularly in the second-line setting [2, 3]. While these intra-arterial interventions can improve median progression-free survival (the time a patient lives without the disease worsening) to 6.7 months compared to 3.8 months with systemic therapy alone (p = 0.009), clinical outcomes remain highly variable [4, 5]. Identifying which individuals will derive a meaningful survival benefit remains a significant challenge for multidisciplinary oncology teams [1, 6]. A recent analysis of the prospective CIREL registry trial now evaluates whether radiomics (the extraction of quantitative data from medical images to uncover disease characteristics invisible to the human eye) can provide the prognostic precision needed to guide treatment, specifically using a baseline intensity algorithm that predicted overall survival with an Area Under the Curve (AUC) of 0.79 (95% CI = 0.57 to 0.95) [7].